Literature DB >> 2127741

Transdermal nitroglycerin (glyceryl trinitrate). A review of its pharmacology and therapeutic use.

P A Todd1, K L Goa, H D Langtry.   

Abstract

Nitroglycerin (glyceryl trinitrate) has been used for many years via the sublingual route for treating acute anginal attacks. In recent years transdermal delivery of nitroglycerin has gained popularity for prophylaxis against angina. However, nitrate tolerance appears to be a therapeutic problem with all long-acting nitrates regardless of delivery mechanism, and it occurs in most patients with stable angina treated with continuous 24-hour application of nitroglycerin patches. Since continuous 24-hour plasma concentrations of nitroglycerin do not appear to be desirable, alternative approaches to therapy are needed. A simple method to minimise tolerance with transdermal nitroglycerin patches is to remove the patch at bedtime and reapply a new patch in the morning. Such intermittent therapy allows a patch-free period during the night, when most patients experience few angina attacks, but optimises nitrate sensitivity during the daytime. However, the place of intermittent nitroglycerin patch therapy in the treatment of stable angina needs clarification with further study, particularly comparisons with other long-acting forms of nitrates. There are insufficient data to recommend the use of transdermal nitroglycerin patches in the treatment of patients with unstable angina or congestive heart failure. In conclusion, transdermal nitroglycerin patches offer a convenient and cosmetically acceptable dosage form which has potential use in stable angina if administered as an intermittent regimen providing a patch-free period each night.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2127741     DOI: 10.2165/00003495-199040060-00009

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  145 in total

1.  Comparison of transdermal nitrate and isosorbide dinitrate in chronic stable angina.

Authors:  D P Nicholls; K Moles; D N Gleadhill; K Booth; J Rowan; P Morton
Journal:  Br J Clin Pharmacol       Date:  1986-07       Impact factor: 4.335

2.  The effects of moderate sustained exercise on the pharmacokinetics of nitroglycerine.

Authors:  S Weber; D de Lauture; E Rey; T Darragon; J P Severins; A Ditisheim; G Olive; M Degeorges
Journal:  Br J Clin Pharmacol       Date:  1987-01       Impact factor: 4.335

3.  Transmucosal and transdermal nitroglycerin delivery systems for prevention of chronic stable angina pectoris.

Authors:  N S Khurmi; M J O'Hara; M J Bowles; J R Whittington; A Lahiri; E B Raftery
Journal:  Br J Clin Pract       Date:  1986-05

Review 4.  Pharmacokinetics of various preparations of organic nitrates.

Authors:  J P Kampmann
Journal:  Drugs       Date:  1987       Impact factor: 9.546

5.  Determination of nitrates in plasma.

Authors:  H Jaeger; D Lutz; K Michaelis; Z B Salama
Journal:  Drugs       Date:  1987       Impact factor: 9.546

6.  Allergic contact dermatitis secondary to transdermal nitroglycerin.

Authors:  A S Rosenfeld; W B White
Journal:  Am Heart J       Date:  1984-10       Impact factor: 4.749

7.  Pharmacokinetic-hemodynamic studies of transdermal nitroglycerin in congestive heart failure.

Authors:  P W Armstrong
Journal:  J Am Coll Cardiol       Date:  1987-02       Impact factor: 24.094

8.  Hemodynamic effects of intermittent transdermal nitroglycerin in chronic congestive heart failure.

Authors:  N Sharpe; R Coxon; M Webster; R Luke
Journal:  Am J Cardiol       Date:  1987-04-01       Impact factor: 2.778

Review 9.  Intravenous glyceryl trinitrate (nitroglycerin). A review of its pharmacological properties and therapeutic efficacy.

Authors:  E M Sorkin; R N Brogden; J A Romankiewicz
Journal:  Drugs       Date:  1984-01       Impact factor: 9.546

10.  [Anti-anginal effect of transdermally applied nitroglycerin as dependent on the size of the plaster].

Authors:  W Schneider; O Michel; M Kaltenbach; W D Bussmann
Journal:  Dtsch Med Wochenschr       Date:  1985-01-18       Impact factor: 0.628

View more
  7 in total

Review 1.  Optimisation of treatment by applying programmable rate-controlled drug delivery technology.

Authors:  Yie W Chien; Senshang Lin
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Mechanisms of gastroprotection by transdermal nitroglycerin in the rat.

Authors:  S Calatayud; M J Sanz; A Canet; R Bello; F D de Rojas; J V Esplugues
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

3.  Effect of pre-treatment with transdermal glyceryl trinitrate on myocardial ischaemia during coronary angioplasty.

Authors:  S Ramamurthy; V Mehan; U Kaufmann; V Verin; T F Lüscher; B Meier
Journal:  Heart       Date:  1996-12       Impact factor: 5.994

4.  The anti-inflammatory and analgesic action of transdermal glyceryltrinitrate in the treatment of infusion-related thrombophlebitis.

Authors:  J R Berrazueta; J J Poveda; J Ochoteco; J A Amado; F Puebla; E Salas; M Sarabia
Journal:  Postgrad Med J       Date:  1993-01       Impact factor: 2.401

5.  Estimation of drug-polymer miscibility and solubility in amorphous solid dispersions using experimentally determined interaction parameters.

Authors:  Patrick J Marsac; Tonglei Li; Lynne S Taylor
Journal:  Pharm Res       Date:  2008-09-09       Impact factor: 4.200

6.  Benefits and safety of transdermal glyceryl trinitrate in acute stroke: a systematic review and meta-analysis of randomised trials (protocol).

Authors:  Beng Leong Lim; Wei Feng Lee; Wei Ming Ng; Wei Ling Tay; Wui Ling Chan
Journal:  BMJ Open       Date:  2021-01-05       Impact factor: 2.692

7.  Pharmacy Malpractice: The rate and prevalence of dispensing high-risk prescription-only medications at community pharmacies in Saudi Arabia.

Authors:  Thamir M Alshammari; Salman A Alhindi; Ahmed M Alrashdi; Imaan Benmerzouga; Mohamad Aljofan
Journal:  Saudi Pharm J       Date:  2016-10-17       Impact factor: 4.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.